MPM backs new biotech in the hunt for non-opi­oid painkiller

A new MPM Cap­i­tal-backed com­pa­ny is join­ing the search for a bet­ter way of treat­ing chron­ic pain.

Six years af­ter its qui­et birth out of a St Louis lab, BioIn­t­er­vene un­veiled an MPM-led $30 mil­lion Se­ries A fund­ing round to take its lead drug, BIO-205, in­to hu­man proof-of-con­cept stud­ies. They an­nounced a new CSO too: Charles Co­hen, a neu­ro­science vet­er­an of Mer­ck, Bay­er, Ver­tex and most re­cent­ly Xenon.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER